Add to ORKGFludarabine in addition to cytosine-arabinoside (ARA-C) increases the accu-mulation of ARA-C–5-triphosphate (ARA-CTP), which is responsible for the cyto-toxic effect in leukemic blasts. In a randomized phase 3 trial, patients with high-risk myelodysplastic syndrome (MDS) (n 91) or elderly patients with acute myeloid leukemia (AML) (n 43) were randomized to receive 2 induction courses consisting of ARA-C (2 g/m2 days 1 through 5) and granulocyte colony-stimulating factor (G-CSF) (filgrastim, 5g/kg) during and after chemotherapy with or without fludarabine (25 mg/m2, days 1 through 5) (FLAG versus AG). Consolidation consisted of daunorubicin (45 mg/m2, days 1 through 3) and ARA-C (200 mg/m2, days 1 through 7). Complete remission (CR) rate f...
The study was designed to compare clofarabine plus daunorubicin vs daunorubicin/ara-C in older patie...
The prognosis of younger patients with intermediate/high risk acute myelogenous leukemia (AML) or hi...
This study aims to determine the maximum tolerated dose (MTD) of clofarabine combined with the EORTC...
Fludarabine in addition to cytosine-arabinoside (ARA-C) increases the accumulation of ARA-C-5'-triph...
Fludarabine in addition to cytosine-arabinoside (ARA-C) increases the accumulation of ARA-C-5'-triph...
Summary Fludarabine plus cytarabine (Ara-C) and idarubicin (FLAI) is an effective and well-tolerated...
The combination of fludarabine, cytarabine (ara-C) and G-CSF (FLAG) is routinely used in the treatme...
Acute Myeloid Leukemia (AML) is the commonest form of leukemia in the adults, with an incidence of 3...
Fludarabine plus cytarabine (Ara-C) and idarubicin (FLAI) is an effective and well-tolerated inducti...
The optimum chemotherapy schedule for reinduction of patients with high-risk acute myeloid leukemia ...
About 105 consecutive acute myeloid leukemia (AML) patients treated with the same induction-consolid...
The study was designed to compare clofarabine plus daunorubicin vs daunorubicin/ara-C in older patie...
Fourteen poor risk acute myeloid leukemia (AML) patients were treated with G-CSF prior (from day 0) ...
The study was designed to compare clofarabine plus daunorubicin vs daunorubicin/ara-C in older patie...
The prognosis of younger patients with intermediate/high risk acute myelogenous leukemia (AML) or hi...
This study aims to determine the maximum tolerated dose (MTD) of clofarabine combined with the EORTC...
Fludarabine in addition to cytosine-arabinoside (ARA-C) increases the accumulation of ARA-C-5'-triph...
Fludarabine in addition to cytosine-arabinoside (ARA-C) increases the accumulation of ARA-C-5'-triph...
Summary Fludarabine plus cytarabine (Ara-C) and idarubicin (FLAI) is an effective and well-tolerated...
The combination of fludarabine, cytarabine (ara-C) and G-CSF (FLAG) is routinely used in the treatme...
Acute Myeloid Leukemia (AML) is the commonest form of leukemia in the adults, with an incidence of 3...
Fludarabine plus cytarabine (Ara-C) and idarubicin (FLAI) is an effective and well-tolerated inducti...
The optimum chemotherapy schedule for reinduction of patients with high-risk acute myeloid leukemia ...
About 105 consecutive acute myeloid leukemia (AML) patients treated with the same induction-consolid...
The study was designed to compare clofarabine plus daunorubicin vs daunorubicin/ara-C in older patie...
Fourteen poor risk acute myeloid leukemia (AML) patients were treated with G-CSF prior (from day 0) ...
The study was designed to compare clofarabine plus daunorubicin vs daunorubicin/ara-C in older patie...
The prognosis of younger patients with intermediate/high risk acute myelogenous leukemia (AML) or hi...
This study aims to determine the maximum tolerated dose (MTD) of clofarabine combined with the EORTC...